# US 2013/0210781 A1 · 23-yne-vitamin d3 derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210781 A1
- Document ID: US20130210781A1
- Status: Published application
- Kind: A1
- Application number: 13/880,637
- Filed: 2011-10-24
- Published: 2013-08-15
- Earliest claimed: 2010-10-25
- Assignees: Teijin Pharma Limited
- Inventors: Hiroshi Saito; Masato Komiyama; Eiji Ochiai; Kenichiro Takagi; Takayuki Chida; Mariko Fujita; Keiichiro Imaizumi; Toshiyuki Kaneko
- Web page: https://patentgrep.com/patent/US20130210781A1

## CPC

- C07C 401/00: Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A61P 11/06: Antiasthmatics
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07C 2601/02: with a three-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2602/24: the ring system containing nine carbon atoms, e.g. perhydroindane
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.

## Claims

### Claim 1

A vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof:
wherein
R1 represents a hydrogen atom, alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.

### Claim 2 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein X represents an oxygen atom.

### Claim 3 (depends on 1)

The vitamin D3 derivative or a pharmaceutically acceptable solvate thereof according to claim 1, wherein X represents a methylene group.

### Claim 4 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein n is 1.

### Claim 5 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein R2 represents a hydrogen atom.

### Claim 6 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein R1 represents a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group, a t-butylcarbonyloxymethyl group, or a phenylcarbonyloxymethyl group.

### Claim 7 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein R2 represents a hydrogen atom and n is 1.

### Claim 8 (depends on 1)

The vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1, wherein R1 represents a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group, a t-butylcarbonyloxymethyl group, or a phenylcarbonyloxymethyl group; R2 represents a hydrogen atom or, together with the other R2 and the carbon atom to which they are bound to, forms a cyclopropyl group; R3 represents a methyl group or an ethyl group, or R3, together with the other R3 and the carbon atom to which they are bound to, forms a cyclopropyl group; X represents an oxygen atom or a methylene group; and n is 1.

### Claim 9

A vitamin D3 derivatives or a medicinally acceptable solvate thereof selected from the group consisting of:
(5Z,7E)-(1R,2S,3R,20R)-2-(2-carboxyethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-methoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-ethoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-propoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-(1-methyl)ethoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-(1,1-dimethyl)ethoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-((t-butylcarbonyloxy)methoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-((phenylcarbonyloxy)methoxycarbonylethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-carboxypropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-methoxycarbonylpropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-ethoxycarbonylpropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-propoxycarbonylpropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-(1-methyl)ethoxycarbonylpropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1S,2S,3R,20R)-2-(2-(1,1-dimethypethoxycarbonylpropyl)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-((2-carboxy-2,2-ethano)ethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-((2-carboxy-2,2-dimethyl)ethoxy)-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol;
(5Z,7E)-(1R,2S,3R,20R)-2-(2-carboxyethoxy)-26,27-dimethyl-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; and
(5Z,7E)-(1R,2S,3R,20R)-2-(2-carboxyethoxy)-26,27-nor-25-cyclopentyl-23-yne-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

A therapeutic agent for one or more diseases selected from the group consisting of osteoporosis, malignant tumor, psoriasis, inflammatory airway disease, rheumatoid arthritis, diabetes mellitus, hypertension, alopecia, acne, and dermatitis, comprising the vitamin D3 derivative or a medicinally acceptable solvate thereof according to claim 1 as an active ingredient.

### Claim 12 (depends on 11)

The therapeutic agent according to claim 11, wherein the disease is osteoporosis.

### Claim 13

A compound represented by the following formula (2):
wherein
R2, X, and n are the same as in the formula (1);
R4 represents R1 in the formula (1), a methoxymethyl group, a methoxyethoxymethyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, or a benzyloxymethyl group; and
R5 represents a protecting group for a hydroxyl group.
